Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

- PMLiVE

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

New indication approved alongside companion diagnostic to detect gene mutation

- PMLiVE

Research units to close as Astellas restructures

US subsidiaries OSI Pharmaceuticals and Perseid Therapeutics among those affected

- PMLiVE

Takeda rides out Actos decline as fiscal 2012 sales rise

Nycomed acquisition continues to bolster revenues

- PMLiVE

Takeda buys vaccines specialist Inviragen

Acquires vaccine candidates against dengue fever and hand, foot and mouth disease in $250m deal

- PMLiVE

FDA committee turns down Aveo/Astellas’ cancer drug

Tivozanib unable to prove superiority to Bayer's Nexavar

Bayer symbol

Bayer expands birth control business with $1.1bn Conceptus acquisition

Adds permanent contraception Essure to portfolio

- PMLiVE

Two new cancer drugs recommended in Europe

CHMP backing for Roche's Erivedge and Astellas' Xtandi

- PMLiVE

Eisai appoints Lynn Kramer chief clinical officer

Says newly created position will strengthen its research base

Astellas appoints Dr Songlin Xue head of global pharmacovigilance

He joins from Takeda and was formerly at Novartis and Wyeth

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

Bayer symbol

Bayer’s riociguat fast-tracked by FDA

Could provide oral option in pulmonary arterial hypertension market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links